About virax biolabs group ltd - VRAX
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.
VRAX At a Glance
Virax Biolabs Group Ltd.
Bo'Ness Road Newhouse
Lanarkshire, Scotland ML1 5UH
| Phone | 44-20-7788-7414 | Revenue | 6.33K | |
| Industry | Financial Conglomerates | Net Income | -6,061,247.00 | |
| Sector | Finance | Employees | 19 | |
| Fiscal Year-end | 03 / 2026 | |||
| View SEC Filings |
VRAX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 671.71 |
| Price to Book Ratio | 0.869 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.029 |
| Enterprise Value to Sales | 26.329 |
| Total Debt to Enterprise Value | 2.262 |
VRAX Efficiency
| Revenue/Employee | 333.211 |
| Income Per Employee | -319,013.00 |
| Receivables Turnover | 0.207 |
| Total Asset Turnover | 0.001 |
VRAX Liquidity
| Current Ratio | 7.269 |
| Quick Ratio | 7.129 |
| Cash Ratio | 6.282 |
VRAX Profitability
| Gross Margin | -6,262.107 |
| Operating Margin | -97,344.811 |
| Pretax Margin | -97,992.308 |
| Net Margin | -95,739.172 |
| Return on Assets | -101.777 |
| Return on Equity | -109.578 |
| Return on Total Capital | -99.804 |
| Return on Invested Capital | -105.132 |
VRAX Capital Structure
| Total Debt to Total Equity | 6.619 |
| Total Debt to Total Capital | 6.208 |
| Total Debt to Total Assets | 5.866 |
| Long-Term Debt to Equity | 5.118 |
| Long-Term Debt to Total Capital | 4.801 |